Advanced Medical Solutions (AMS) AI Stock Analysis

• Market Cap: £473.43M
• Dividend Yield: 1.21%
• Average Volume (3M): 514.34K
• Price to Earnings (P/E): 52.0
• Beta (1Y): 1.52
• Revenue Growth: 68.03%
• EPS Growth: -18.27%
• Country: UK
• Employees: 1,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.06
• Shares Outstanding: 219,380,310
• 10 Day Avg. Volume: 735,778
• 30 Day Avg. Volume: 514,343
• PEG Ratio: -1.08
• Price to Book (P/B): 1.76
• Price to Sales (P/S): 2.39
• P/FCF Ratio: 33.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £273.67
• Price Target Upside: 24.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 64 Neutral
• Price Target: 221.00p ▲(0.91% Upside)

The overall stock score of 64 reflects strong financial performance with robust revenue growth and a solid capital structure. However, high P/E ratio and declining profitability margins are concerns. Technical indicators show a positive trend, but valuation metrics suggest caution.

Positive Factors

Revenue Growth

The substantial revenue growth indicates strong demand for AMS's products, suggesting successful market penetration and potential for continued expansion.

Cash Flow Health

Improved cash-generating capability enhances AMS's ability to reinvest in growth opportunities and maintain financial flexibility, supporting long-term stability.

Solid Capital Structure

A strong capital structure with moderate leverage ensures financial stability and provides AMS with the resilience to withstand economic fluctuations.

Negative Factors

Declining Profit Margins

Decreasing profit margins highlight potential cost management issues or increased competition, which could pressure AMS's profitability if not addressed.

Reduced Return on Equity

A declining return on equity suggests reduced efficiency in generating returns from shareholder investments, potentially impacting investor confidence.

High Capital Expenditures

Increased capital expenditures, while potentially growth-oriented, constrain free cash flow, limiting AMS's ability to allocate resources to other strategic initiatives.

Advanced Medical Solutions Business Overview & Revenue Model

Company Description

Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, France, rest of Europe, the United States, and internationally. It operates in two segments, Surgical and Woundcare. The Surgical segment offers topical tissue adhesives for wound closure and sealing under the LiquiBand brand; sutures and collagen-based products for the surgical and dental markets under the RESORBA brand; collagens; and laparoscopic device used to fix hernia meshes placed inside the body under the LiquiBand Fix8 brand, as well as internal sealants under the Seal-G/Seal-G MIST brand. The Woundcare segment provides wound care platform technologies, which include alginates, foams, films, fibres, hydrogels, antimicrobial dressings, and hydrocolloids, as well as wound care products under the ActivHeal brand. Advanced Medical Solutions Group plc was incorporated in 1991 and is headquartered in Winsford, the United Kingdom.

How the Company Makes Money

AMS generates revenue through multiple streams, primarily by selling its medical products directly to hospitals, clinics, and healthcare providers. The company also engages in long-term contracts and partnerships with healthcare organizations, which provide a steady income through bulk purchases and exclusive supply agreements. Additionally, AMS invests in research and development to innovate new products, which can lead to higher sales volumes and premium pricing. The company may also generate income from licensing agreements for its technology and collaborating with other firms on joint ventures that expand its market reach.

Advanced Medical Solutions Financial Statement Overview

Summary

Advanced Medical Solutions shows strong revenue growth and a solid capital structure. However, declining profitability margins and return on equity suggest potential operational inefficiencies or increased costs. The company's cash flow remains healthy, with a significant increase in operating cash flow, but free cash flow has been constrained by higher capital expenditures.

Income Statement

The company demonstrates a strong gross profit margin of 46.6% in 2024, indicating efficient cost management. However, the net profit margin has decreased from 12.6% in 2023 to 4.0% in 2024, suggesting increased expenses or lower operating efficiency. Revenue growth from 2023 to 2024 shows a significant increase of 40.6%, indicating robust demand for the company's products. EBIT and EBITDA margins have decreased to 5.9% and 16.7% respectively in 2024, highlighting potential operational challenges.

Balance Sheet

The balance sheet reflects a solid equity base with a debt-to-equity ratio of 0.36 in 2024, suggesting moderate leverage and financial stability. The equity ratio remains healthy at 61.9% in 2024, underscoring a strong capital structure. However, the return on equity has declined to 2.9% in 2024 from 6.5% in 2023, indicating reduced profitability relative to shareholder investments.

Cash Flow

Operating cash flow has increased by 35.5% from 2023 to 2024, reflecting improved cash-generating capability. However, free cash flow has decreased due to higher capital expenditures. The operating cash flow to net income ratio is 2.36 in 2024, indicating strong cash flow relative to earnings. Nonetheless, the free cash flow to net income ratio is 1.79, which is robust, although lower than previous years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	220.30M	177.52M	126.21M	124.33M	108.60M	86.80M
Gross Profit	108.40M	82.77M	70.14M	68.62M	56.12M	42.67M
EBITDA	37.81M	29.68M	31.40M	34.94M	31.55M	17.53M
Net Income	9.17M	7.09M	15.89M	20.41M	17.48M	8.58M
Balance Sheet
Total Assets	397.44M	389.00M	289.17M	281.09M	249.51M	238.56M
Cash, Cash Equivalents and Short-Term Investments	19.34M	17.04M	60.16M	82.26M	72.97M	53.83M
Total Debt	82.38M	86.56M	9.14M	9.75M	9.86M	11.12M
Total Liabilities	140.50M	147.48M	44.97M	44.47M	36.83M	36.34M
Stockholders Equity	256.24M	240.78M	244.20M	236.62M	212.68M	202.21M
Cash Flow
Free Cash Flow	19.17M	12.67M	2.50M	17.12M	23.95M	15.79M
Operating Cash Flow	24.04M	16.73M	12.35M	27.08M	30.41M	21.05M
Investing Cash Flow	-65.83M	-67.15M	-20.27M	-12.70M	-6.41M	-27.05M
Financing Cash Flow	-70.55M	5.48M	-13.62M	-5.70M	-4.41M	-5.09M

Advanced Medical Solutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 219.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AMS, the sentiment is Positive. The current price of 219 is above the 20-day moving average (MA) of 213.37, above the 50-day MA of 207.49, and above the 200-day MA of 203.89, indicating a bullish trend. The MACD of 4.08 indicates Negative momentum. The RSI at 56.42 is Neutral, neither overbought nor oversold. The STOCH value of 43.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AMS.

Advanced Medical Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	74 Outperform	£174.20M	28.08	19.61%	3.88%	10.32%	1.25%
CTEC	70 Outperform	£4.78B	29.11	12.73%	2.11%	4.18%	37.65%
AMS	64 Neutral	£473.43M	52.00	3.66%	1.21%	68.03%	-18.27%
PRTC	59 Neutral	£334.97M	9.71	15.04%	―	1231.50%	―
AGY	56 Neutral	£395.61M	―	-369.20%	―	4.50%	74.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Advanced Medical Solutions Corporate Events

Advanced Medical Solutions Reports Strong H1 2025 Results with Revenue Boost from Acquisition

Advanced Medical Solutions Group plc reported strong interim results for the first half of 2025, with a 63% increase in group revenue to £110.8 million, driven by the acquisition of Peters Surgical and organic growth. The integration of Peters Surgical and Syntacoll has contributed positively, enhancing manufacturing efficiencies and expanding market presence, particularly in cardiovascular markets. Despite a slight reduction in gross margins, the company achieved a 42% increase in adjusted EBITDA and a 49% rise in profit before tax. The restructuring of the Woundcare business has been completed, positioning it as a cash-generative unit. AMS remains optimistic about sustaining growth, with plans for US product launches and further deleveraging by year-end.

The most recent analyst rating on (GB:AMS) stock is a Hold with a £216.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Seeks Block Listing for 10.4 Million Shares on AIM

Advanced Medical Solutions Group plc has applied to the London Stock Exchange for the block listing of 10,400,000 ordinary shares to be admitted to trading on AIM. This application involves shares issued under various company share schemes, with no change to the current issued share capital. The admission of these shares is expected to take effect on 15 September 2025, and they will rank equally with existing shares. This move is part of AMS’s ongoing strategy to support its growth and operational flexibility.

The most recent analyst rating on (GB:AMS) stock is a Hold with a £221.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Announces Total Voting Rights Update

Advanced Medical Solutions Group plc announced its total issued share capital as of August 29, 2025, comprising 219,330,534 ordinary shares, each with voting rights, with no shares held in treasury. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.

The most recent analyst rating on (GB:AMS) stock is a Hold with a £219.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions to Announce Interim Results for H1 2025

Advanced Medical Solutions Group plc announced it will release its interim results for the first half of 2025 on September 17. The company will hold a briefing for analysts and a presentation for shareholders, highlighting its commitment to transparency and stakeholder engagement. This announcement underscores AMS’s ongoing efforts to maintain its strong market position and provide value to its investors.

The most recent analyst rating on (GB:AMS) stock is a Hold with a £219.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Announces Share Capital Update

Advanced Medical Solutions Group plc announced that its issued share capital as of July 31, 2025, consists of 219,288,700 ordinary shares with voting rights, with no shares held in treasury. This information is relevant for shareholders to determine their notification obligations under the FCA’s Disclosure and Transparency Rules. The announcement reflects AMS’s commitment to transparency and regulatory compliance, which may impact shareholder engagement and market perception.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.

Advanced Medical Solutions Reports Strong H1 2025 Growth

Advanced Medical Solutions Group plc reported strong growth in the first half of 2025, driven by momentum in its core surgical product portfolio and successful integration of recent acquisitions, Peters Surgical and Syntacoll. The restructuring of its Woundcare business has improved margins, contributing to the Group’s expected half-year revenue of approximately £110 million, up from £68 million in the previous year. The company remains confident in meeting full-year forecasts, with significant synergies anticipated from ongoing integrations.

The most recent analyst rating on (GB:AMS) stock is a Buy with a £2.45 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.